MKI67 and glioblastoma: However, it remains to be elucidated if DNA methylation of the four enhancers targeted is associated with SNP genotypes, e.g., MGMT rs16906252, and/or clinicopathological characteristics, including the proliferation marker Ki-67, progression-free survival, and the response to TMZ in GBM.